Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Operations: 2010-2021

Historic Cash from Operations for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2021 value amounting to $4.2 million.

  • Neurocrine Biosciences' Cash from Operations fell 95.56% to $4.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $256.5 million, marking a year-over-year increase of 12.25%. This contributed to the annual value of $595.4 million for FY2024, which is 52.71% up from last year.
  • According to the latest figures from Q4 2021, Neurocrine Biosciences' Cash from Operations is $4.2 million, which was down 93.20% from $61.8 million recorded in Q3 2021.
  • Neurocrine Biosciences' 5-year Cash from Operations high stood at $118.9 million for Q2 2020, and its period low was -$112.5 million during Q1 2019.
  • Its 3-year average for Cash from Operations is $52.7 million, with a median of $75.8 million in 2019.
  • As far as peak fluctuations go, Neurocrine Biosciences' Cash from Operations plummeted by 236.51% in 2017, and later skyrocketed by 840.25% in 2018.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Cash from Operations stood at $40.6 million in 2017, then increased by 24.44% to $50.5 million in 2018, then soared by 93.11% to $97.5 million in 2019, then decreased by 3.08% to $94.5 million in 2020, then plummeted by 95.56% to $4.2 million in 2021.
  • Its Cash from Operations stands at $4.2 million for Q4 2021, versus $61.8 million for Q3 2021 and $103.2 million for Q2 2021.